Abstract
Overexpression of MCL-1 is an antiapoptotic member of the BCL-2 family and has been seen in various human tumors,correlating with the patient’s poor prognosis. This study tested whether cancers overexpress MCL-1 to gain resistance tovenetoclax. The expression of MCL-1 protein was measured by Western blot. Cell viability after venetoclax and MCL-1inhibitor AZD5991 was added was measured by MTT. FP-based binding assays measured Venetoclax’s binding affinityfor MCL-1. The result of the study would give insights into venetoclax resistance and the overexpression of MCL-1 inNHL OCI-Ly1. Future studies should focus on new drugs that can circumvent this resistance if the hypothesis is correct.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
